Collectively, our findings establish SE-driven SOX4 and SMAD3 as key regulators in CML-BP and identify Bemcentinib as a promising therapeutic strategy. The gene discussed is SMAD3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.